Trans-Oval-Window Implants, A New Approach for Drug Delivery to the Inner Ear: Extended @entity619 Release From XXXX -based Implants.

@entity3784 @entity619 @entity1346 @entity389 @entity968 @entity288
HYPOTHESIS: The purpose of this study was to develop a new strategy to deliver drugs to the inner ear from @entity619 ( @entity3784 )-loaded silicone implants and to evaluate the distribution of the drug in the cochlea with confocal microscopy. BACKGROUND: Systemic drug administration for the treatment of @entity389 is tricky because of the blood-cochlear barrier, a difficult anatomical access, the small size of the cochlea, and can cause significant adverse effects. An effective way to overcome these obstacles is to administer drugs locally. METHODS: In vitro, the drug release from @entity3784 -loaded @entity1346 -based thin films and tiny implants into artificial perilymph was thoroughly analyzed by high-performance liquid chromatography. In vivo, a silicone implant loaded with 10% @entity3784 and 5% @entity968 was implanted next to the stapes's footplate of gerbils. Delivery of @entity3784 into the inner ear was proved by confocal microscopy imaging of the whole cochlea and the organ of Corti. RESULTS: The study showed a continuous and prolonged release during 90 days in vitro. This was confirmed by confocal microscopy that allowed detection of @entity3784 by fluorescence labeling in the cell body of the hair cells for at least 30 days. Interestingly, fluorescence was already observed after 20 minutes of implantation, reached a climax at day 7, and could still be detected 30 days after implantation. CONCLUSIONS: Thus, we developed a new device for local @entity288 delivery into the oval window with an extended drug release of @entity3784 to the inner ear.
